Oral intake of medication

ApprovedSmall molecule

SShahid Beheshti University of Medical Sciences

Oral intake of medication is one of 66 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Age-Related Macular DegenerationActive, not recruiting

Premature EjaculationActive, not recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Premature EjaculationApproved

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

44 2

Lucentis

Roche

Phase 3

64 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Aquasol E

NNational Eye Institute (NEI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 1·NCT05005884·80 enrolled

Premature Ejaculation1 trial

Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation

Completed·—·Phase 4·NCT07113145·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oral intake of medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral intake of medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral intake of medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShahid Beheshti University of Medical Sciences

Oral intake of medication

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News